DeepMed Research

VistaGen Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1998-01-01

Employees: 40

Market Cap: $95.5M

Website: http://www.vistagen.com

Introduction: Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Clinical Trials

A U.S. Double-blind, Placebo-controlled Phase 2 Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder

Phase 2

Recruiting

Conditions: Social Anxiety Disorder

Interventions: Drug: Fasedienol Nasal Spray - Placebo Nasal Spray
Drug: Fasedienol Nasal Spray - Fasedienol Nasal Spray
Drug: Placebo Nasal Spray - Placebo Nasal Spray

First Posted Date: 2025-02-05

Last Posted Date: 2025-02-19

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 60

Registration Number: NCT06809179

Locations: 🇺🇸
Vistagen Clinical Site, Cleveland, Ohio, United States

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Phase 3

Recruiting

Conditions: Social Anxiety Disorder (SAD)

Interventions: Drug: Fasedienol Nasal Spray
Drug: Placebo Nasal Spray

First Posted Date: 2024-09-26

Last Posted Date: 2025-04-15

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 236

Registration Number: NCT06615557

Locations: 🇺🇸
Vistagen Clinical Site, Houston, Texas, United States

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-3)

Phase 3

Recruiting

Conditions: Social Anxiety Disorder

Interventions: Drug: Placebo Nasal Spray
Drug: Fasedienol Nasal Spray

First Posted Date: 2024-04-10

Last Posted Date: 2025-02-19

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 236

Registration Number: NCT06358651

Locations: 🇺🇸
Vistagen Clinical Site, Everett, Washington, United States

AV-101 Alone and in Combination With Probenecid in Healthy Subjects

Phase 1

Conditions: Drug Drug Interaction

Interventions: Drug: AV-101
Drug: Probenecid

First Posted Date: 2022-03-15

Last Posted Date: 2022-03-15

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 24

Registration Number: NCT05280054

Locations: 🇺🇸
Parexel Early Phase Clinical Unit, Glendale, California, United States

Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)

Phase 3

Terminated

Conditions: Social Anxiety Disorder

Interventions: Drug: PH94B

First Posted Date: 2021-09-01

Last Posted Date: 2023-09-21

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 483

Registration Number: NCT05030350

Locations: 🇺🇸
VistaGen Investigational Site, Bellevue, Washington, United States

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

Phase 3

Terminated

Conditions: Social Anxiety Disorder

Interventions: Drug: PH94B Nasal Spray
Drug: Placebo Nasal Spray

First Posted Date: 2021-08-18

Last Posted Date: 2023-07-13

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 324

Registration Number: NCT05011396

Locations: 🇺🇸
VistaGen Clinical Center, Allentown, Pennsylvania, United States
🇺🇸
VistaGen Clinical Site, Austin, Texas, United States

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge

Phase 3

Completed

Conditions: Social Anxiety Disorder

Interventions: Drug: PH94B Nasal Spray
Drug: Placebo Nasal Spray

First Posted Date: 2021-02-15

Last Posted Date: 2022-06-23

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 209

Registration Number: NCT04754802

Locations: 🇺🇸
VistaGen Clinical Sites, Fort Myers, Florida, United States
🇺🇸
VistaGen Clinical Site, Bellevue, Washington, United States

PH94B in the Treatment of Adjustment Disorder With Anxiety

Phase 2

Completed

Conditions: Adjustment Disorder With Anxious Mood

Interventions: Drug: Placebo
Drug: PH94B

First Posted Date: 2020-05-27

Last Posted Date: 2023-12-11

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 41

Registration Number: NCT04404192

Locations: 🇺🇸
VistaGen Clinical Site, New York, New York, United States

AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Phase 2

Conditions: L-Dopa Causing Adverse Effects in Therapeutic Use
Dyskinesia, Medication-Induced
Parkinson Disease

Interventions: Drug: Placebo
Drug: AV-101

First Posted Date: 2019-11-01

Last Posted Date: 2021-05-26

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 20

Registration Number: NCT04147949

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: AV-101
Drug: Placebo

First Posted Date: 2017-03-13

Last Posted Date: 2019-10-09

Lead Sponsor: VistaGen Therapeutics, Inc.

Target Recruit Count: 180

Registration Number: NCT03078322

Locations: 🇺🇸
VistaGen Investigational Site, Bellevue, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy